Dorzolamide hydrochloride eye drops 2% (Trusopt): Discontinuation
Mundipharma has notified that it will discontinue the supply of dorzolamide hydrochloride (Trusopt) eye drops 2% (pharmacode 285226).
Current supply of dorzolamide eye drops 2% (Pharmacode: 285226) is expected to be depleted by the end of September 2023.
1 April 2023: We limited access to people who were taking dorzolamide hydrochloride eye drops 2% before this date.
September 2023: Existing stock of dorzolamide hydrochloride eye drops 2% is expected to be exhausted.
1 March 2024: Dorzolamide hydrochloride eye drops 2% will no longer be funded.
No new patients from 1 April 2023
We want to ensure supply of dorzolamide hydrochloride eye drops 2% for existing patients for as long as possible. This will give people time to talk to their prescriber about alternative treatments.
To achieve this, we have restricted dispensing to people who were using this treatment before 1 April 2023.
Pharmacists can endorse the script where they have a record of a previous dispensing of dorzolamide hydrochloride eye drops 2%.
Alternatives to dorzolamide hydrochloride eye drops 2%
There are a number of fully funded treatment options available. Where appropriate, we encourage prescribers to discuss alternative options with their patients.
Who to contact
If you take dorzolamide hydrochloride eye drops 2%, please talk to your pharmacist, doctor or the person who prescribed this medicine. They are best placed to discuss your individual clinical circumstances.
If you have a question about funding for dorzolamide eye drops or alternative treatments, email firstname.lastname@example.org